Impact of spleen volume and volume change in non-Hodgkin lymphoma treated with chimeric antigen receptor t-cell therapy.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
68 patients, responders had a significantly greater SVC decrease from BL to FU1 than non-responders (p = 0.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
In combination with SI, SVC was significantly associated with PFS (p = 0.049), but not OS. [CONCLUSION] This study demonstrated that the early change in SV is associated with PFS and OS, regardless of splenic involvement and should be explored as a potential novel dynamic biomarker in the context of lymphoma patients receiving CART.
[PURPOSE] Chimeric antigen receptor T-cell (CART) therapy targeting CD19 is effective for relapsed/refractory (r/r) lymphoma.
- p-value p = 0.001
- p-value p = 0.056
APA
Quell C, Kunz WG, et al. (2026). Impact of spleen volume and volume change in non-Hodgkin lymphoma treated with chimeric antigen receptor t-cell therapy.. Cancer treatment and research communications, 46, 101080. https://doi.org/10.1016/j.ctarc.2025.101080
MLA
Quell C, et al.. "Impact of spleen volume and volume change in non-Hodgkin lymphoma treated with chimeric antigen receptor t-cell therapy.." Cancer treatment and research communications, vol. 46, 2026, pp. 101080.
PMID
41496263 ↗
Abstract 한글 요약
[PURPOSE] Chimeric antigen receptor T-cell (CART) therapy targeting CD19 is effective for relapsed/refractory (r/r) lymphoma. As part of the lymphatic system, the spleen might influence CART outcomes. We examined how spleen volume (SV) and its changes affect progression-free (PFS) and overall survival (OS).
[METHODS] Patients with baseline (BL) and 30-day follow-up (FU1) (PET)/CT scans were included. Spleens were 3D-segmented, and volume change (SVC) from BL to FU1 was calculated. Treatment response, overall response rate, and PFS were evaluated by Lugano criteria.
[RESULTS] Among 68 patients, responders had a significantly greater SVC decrease from BL to FU1 than non-responders (p = 0.001). Those with baseline splenic involvement (SI) showed a smaller, non-significant SVC decrease (p = 0.056). Survival analysis showed significant differences in OS (167 vs. 390 days, p = 0.040) and PFS (79 vs. 327 days, p = 0.008) based on median SVC. In combination with SI, SVC was significantly associated with PFS (p = 0.049), but not OS.
[CONCLUSION] This study demonstrated that the early change in SV is associated with PFS and OS, regardless of splenic involvement and should be explored as a potential novel dynamic biomarker in the context of lymphoma patients receiving CART.
[METHODS] Patients with baseline (BL) and 30-day follow-up (FU1) (PET)/CT scans were included. Spleens were 3D-segmented, and volume change (SVC) from BL to FU1 was calculated. Treatment response, overall response rate, and PFS were evaluated by Lugano criteria.
[RESULTS] Among 68 patients, responders had a significantly greater SVC decrease from BL to FU1 than non-responders (p = 0.001). Those with baseline splenic involvement (SI) showed a smaller, non-significant SVC decrease (p = 0.056). Survival analysis showed significant differences in OS (167 vs. 390 days, p = 0.040) and PFS (79 vs. 327 days, p = 0.008) based on median SVC. In combination with SI, SVC was significantly associated with PFS (p = 0.049), but not OS.
[CONCLUSION] This study demonstrated that the early change in SV is associated with PFS and OS, regardless of splenic involvement and should be explored as a potential novel dynamic biomarker in the context of lymphoma patients receiving CART.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.